| 12:00 – 15:00 |
Workshop 1
Public Health, Transmission, and Community Engagement
Ensuring blood safety, and interrupting HTLV transmission
Sheila O ’Brien
HTLV-1 Pre-Exposure Prophylaxis Working Group
Fabiola Martin
Public heath impact of HTLV in vulnerable populations and geographic areas in Peru
Eduardo Gotuzzo
HTLV transmission in Europe
Andrea Thoma-Kress
Status of HTLV-1 in Aboriginals communities
Lloyd Einsiedel
HTLV challenges and opportunities in the international public health agenda
Peter Figueroa
|
Workshop 2
Molecular Virology and Immunopathogenesis
Molecular Virology of HTLV
Benoit Barbeau, Canada
Mechanisms of latent HTLV-1 infection, clonal evolution and genetic landscape of ATLL
Yorifumi Satou
HTLV-1-induced immune dysfunction
Helene Dutartre
HTLV-1 particle assembly and transmission
Louis Mansky
HTLV-1 immunopathogenesis
Sharron Manuel
Genetic landscape and clonal evolution of ATLL
Aileen Rowan
|
| 15:30 – 17:30 |
Workshop 3
HTLV epidemiology, phylogenetics, and diagnostics
Standardizing molecular diagnosis of HTLV infections
Philippa Hetzel
Genetic diversity of HTLV-1 and its molecular epidemiology Philippe Afonso
Diagnosis of HTLV infections in early life
Carolina Rosadas
Prognostic – CNS Biomarkers of HTLV-associated neuroinflammation
Yoshi Yamano
Molecular epidemiology of HTLVs in the Americas
Antonio Vallinoto
IRVA Africa meeting, safety of blood transfusions in Africa and the need to inform public policy
Jean-Claude Twizere
|
Workshop 4
Preclinical models, clinical guidelines, and trials
HTLV animal models (ATLL & HAM/TSP)
Patrick Green
US National Cancer Research Network (NCCN) guidelines
Steven Horwitz
Targeting Epigenetic and Other Pathways in ATLL
Toshiki Watanabe
Evidence-based treatment recommendations for ATLL
Lucy Cook
Advances in Stem Cell Transplant for ATLL
Ali Bazarbachi
Current & emerging therapeutic strategies for ATLL in USA
Georgios Pongas
|
